Last edition
News about "Dr. Anders Gabrielsen"
Ribo Submits Phase 2 EMA Trial Application for siRNA Therapy in Thromboembolic Disease
Ribo submits a Phase 2 clinical trial application to the European Medicines Agency (EMA) for its siRNA therapeutic targeting thromboembolic disease, advancing development of innovative oligonucleotide-based therapies for Coronary Artery Disease (CAD)
Dr. Anders Gabrielsen | 28/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members